Improving Asthma Treatment and Diagnosis in Children Using Digital and Standard Inhalers Study of New Digital Spacer to Support Inhaled Corticosteroid Use in Children Aged 5 to 16

What this Trial Is About

Asthma is a common chronic condition in children that requires proper inhaler use and consistent medication to manage symptoms effectively. This research aims to study if a new digital inhaler can improve how well children aged 5 to 16 with partly controlled or uncontrolled asthma use their inhaled corticosteroids. The study also looks at biological markers and environmental factors that might affect asthma control and treatment response in these children. Participants with asthma will be randomly assigned to use either a standard inhaler called AeroChamber Plus Flow-Vu or a new digital inhaler called the Whizz spacer, which monitors inhalation and links to a mobile app. Both groups will use their assigned inhaler for 12 weeks. Additionally, children without asthma will be included for a single visit to provide comparison biological samples. During the study, children will complete daily diaries of their inhaler use and asthma control questionnaires at the start, middle, and end of the 12 weeks. They will undergo lung function tests, give biological samples, and provide dust samples from their bedrooms. Physical activity will be tracked using a bracelet worn for 7 days at the beginning and end of the study. Researchers will measure adherence to treatment, asthma control, inflammatory markers, and environmental exposure throughout the trial.

Advancing Diagnosis and Treatment of Pediatric Asthma